Barclays Cuts Agilent Technologies (NYSE:A) Price Target to $140.00

Agilent Technologies (NYSE:A) had its target price decreased by Barclays from $150.00 to $140.00 in a research note released on Tuesday,Benzinga reports. Barclays currently has an overweight rating on the medical research company’s stock.

Several other equities analysts have also recently issued reports on A. HSBC assumed coverage on Agilent Technologies in a report on Tuesday, January 20th. They set a “buy” rating and a $180.00 price objective for the company. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Agilent Technologies in a report on Monday, December 29th. Evercore raised Agilent Technologies from an “in-line” rating to an “outperform” rating and lifted their price objective for the stock from $155.00 to $160.00 in a report on Monday, January 5th. TD Cowen reduced their price objective on Agilent Technologies from $170.00 to $157.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Finally, UBS Group reduced their price objective on Agilent Technologies from $180.00 to $165.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Agilent Technologies currently has a consensus rating of “Moderate Buy” and an average price target of $160.53.

Agilent Technologies Trading Down 1.4%

NYSE:A opened at $118.13 on Tuesday. The stock’s 50 day moving average price is $118.26 and its 200 day moving average price is $133.90. The company has a market capitalization of $33.38 billion, a PE ratio of 26.08, a P/E/G ratio of 2.52 and a beta of 1.30. The company has a quick ratio of 1.59, a current ratio of 2.07 and a debt-to-equity ratio of 0.44. Agilent Technologies has a 52-week low of $99.12 and a 52-week high of $160.27.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, February 25th. The medical research company reported $1.36 earnings per share for the quarter, missing analysts’ consensus estimates of $1.37 by ($0.01). Agilent Technologies had a return on equity of 24.49% and a net margin of 18.26%.The company had revenue of $1.80 billion for the quarter, compared to analyst estimates of $1.81 billion. During the same period in the previous year, the business posted $1.31 earnings per share. The firm’s revenue was up 7.0% compared to the same quarter last year. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. On average, research analysts anticipate that Agilent Technologies will post 5.58 EPS for the current year.

Agilent Technologies Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 22nd. Shareholders of record on Tuesday, March 31st will be given a dividend of $0.255 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $1.02 annualized dividend and a yield of 0.9%. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.52%.

Institutional Investors Weigh In On Agilent Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC grew its position in Agilent Technologies by 107.2% during the first quarter. SG Americas Securities LLC now owns 1,674,856 shares of the medical research company’s stock valued at $190,900,000 after acquiring an additional 866,641 shares during the period. Evolve Private Wealth LLC grew its position in Agilent Technologies by 7.4% during the first quarter. Evolve Private Wealth LLC now owns 7,574 shares of the medical research company’s stock valued at $863,000 after acquiring an additional 523 shares during the period. Vaughan Nelson Investment Management L.P. grew its position in Agilent Technologies by 2.2% during the first quarter. Vaughan Nelson Investment Management L.P. now owns 207,277 shares of the medical research company’s stock valued at $23,625,000 after acquiring an additional 4,535 shares during the period. Triad Wealth Partners LLC grew its position in Agilent Technologies by 14.4% during the first quarter. Triad Wealth Partners LLC now owns 2,546 shares of the medical research company’s stock valued at $290,000 after acquiring an additional 321 shares during the period. Finally, Davis Capital Management grew its position in Agilent Technologies by 30.6% during the first quarter. Davis Capital Management now owns 6,957 shares of the medical research company’s stock valued at $793,000 after acquiring an additional 1,632 shares during the period.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.